P. Hillemanns, K. Lindemann, J. Baurain, P. Blecharz, K. B. Slot, K. Schjetne, S. Torhaug, A. Fredriksen
{"title":"特异性靶向抗原细胞提呈细胞的治疗性DNA疫苗VB10.16联合atezolizumab治疗晚期hpv16阳性宫颈癌患者的疗效和安全性:一项预先计划的中期分析结果","authors":"P. Hillemanns, K. Lindemann, J. Baurain, P. Blecharz, K. B. Slot, K. Schjetne, S. Torhaug, A. Fredriksen","doi":"10.1136/ijgc-2022-esgo.26","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":114847,"journal":{"name":"Cervical cancer","volume":"33 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"2022-RA-447-ESGO Efficacy and safety of VB10.16, a therapeutic DNA vaccine specifically targeting antigen-cell presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer: results from a pre-planned interim analysis\",\"authors\":\"P. Hillemanns, K. Lindemann, J. Baurain, P. Blecharz, K. B. Slot, K. Schjetne, S. Torhaug, A. Fredriksen\",\"doi\":\"10.1136/ijgc-2022-esgo.26\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":114847,\"journal\":{\"name\":\"Cervical cancer\",\"volume\":\"33 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cervical cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2022-esgo.26\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cervical cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-esgo.26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
2022-RA-447-ESGO Efficacy and safety of VB10.16, a therapeutic DNA vaccine specifically targeting antigen-cell presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer: results from a pre-planned interim analysis